{"entity":{"id":"ccga","kind":"trial","name":"CCGA (Circulating Cell-free Genome Atlas)","aka":["CCGA","Circulating Cell-free Genome Atlas","GRAIL-001"],"tldr":"The case-control study of about 15,000 people with and without cancer that GRAIL used to build and validate the Galleri blood test.","summary":"CCGA (NCT02889978) is an observational study sponsored by GRAIL, Inc. It collected blood from people newly diagnosed with cancer and from people without cancer so that GRAIL could compare sequencing approaches, train the targeted methylation classifier that became Galleri, and test its accuracy in three substudies (Liu 2020 for the second, Klein 2021 for the third, independent validation set).\n\nThe registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 13 September 2023), with 15,254 participants enrolled, a start on 4 August 2016 and primary completion expected in March 2024.","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT02889978","url":"https://clinicaltrials.gov/study/NCT02889978"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":["galleri"],"companies":["grail"],"institutions":[],"pathways":[],"terms":["ccga-study"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-liu-ccga2-methylation-ann-oncol-2020","paper-klein-ccga3-mced-validation-ann-oncol-2021","paper-jamshidi-ccga1-cfdna-approaches-cancer-cell-2022"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02889978","phase":"observational","setting":"People with a new cancer diagnosis and people without cancer in the United States and Canada, giving blood (and tumour tissue where available) to train and validate a cell-free DNA cancer classifier","sponsor":"GRAIL, Inc.","started":"2016-08-04","startedType":"actual","yearReported":2021,"enrolled":15254,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/ccga/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/"}],"company":[{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/"}],"term":[{"id":"ccga-study","kind":"term","name":"CCGA: the Circulating Cell-free Genome Atlas behind the Galleri methylation test","route":"/terms/ccga-study/"}],"paper":[{"id":"paper-klein-ccga3-mced-validation-ann-oncol-2021","kind":"paper","name":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","route":"/key-papers/paper-klein-ccga3-mced-validation-ann-oncol-2021/"},{"id":"paper-jamshidi-ccga1-cfdna-approaches-cancer-cell-2022","kind":"paper","name":"Evaluation of cell-free DNA approaches for multi-cancer early detection","route":"/key-papers/paper-jamshidi-ccga1-cfdna-approaches-cancer-cell-2022/"},{"id":"paper-liu-ccga2-methylation-ann-oncol-2020","kind":"paper","name":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","route":"/key-papers/paper-liu-ccga2-methylation-ann-oncol-2020/"}]}}